Abstract:Hepatorenal syndrome (HRS) is a serious form of renal dysfunction in patients with cirrhosis and ascites. It is an important component of the acute-on-chronic liver failure (ACLF) syndrome. Significant recent changes in the understanding of the pathophysiology of renal dysfunction in cirrhosis include the role of inflammation in addition to hemodynamic changes. The term acute kidney injury (AKI) is now adopted to include all functional and structural forms of acute renal dysfunction in cirrhosis, with various stages describing the severity of the condition. Type 1 hepatorenal syndrome (HRS1) is renamed HRS-AKI, which is stage 2 AKI [doubling of baseline serum creatinine (sCr)] while fulfilling all other criteria of HRS1. Albumin is used for its volume expanding and anti-inflammatory properties to confirm the diagnosis of HRS-AKI. Vasoconstrictors are added to albumin as pharmacotherapy to improve the hemodynamics. Terlipressin, although not yet available in North America, is the most common vasoconstrictor used worldwide. Patients with high grade of ACLF treated with terlipressin are at risk for respiratory failure if there is pretreatment respiratory compromise. Norepinephrine is equally effective as terlipressin in reversing HRS1. Recent data show that norepinephrine may be administered outside the intensive care setting, but close monitoring is still required. There has been no improvement in overall or transplant-free survival shown with vasoconstrictor use, but response to vasoconstrictors with reduction in sCr is associated with improvement in survival. Non-responders to vasoconstrictor plus albumin will need liver transplantation as definite treatment with renal replacement therapy as a bridge therapy. Combined liver and kidney transplantation is recommended for patients with prolonged history of AKI, underlying chronic kidney disease or with hereditary renal conditions. Future developments, such as the use of biomarkers and metabolomics, may help to identify at risk patients with earlier diagnosis to allow for earlier treatment with improved outcomes.

Emphasis on the Basic and Clinical Research on Hepatorenal Syndrome

Management of hepatorenal syndrome in liver cirrhosis: a recent update

Progress on treatment of hepatorenal syndrome

Hepatorenal Syndrome in Cirrhosis

Risk Factors, Diagnosis, and Updated Classification of Hepatorenal Syndrome

Research progress in diagnosis and treatment of hepatorenal syndrome

Clinical advances on hepatorenal syndrome research

Concerns for the recent progression of hepatorenal syndrome

Advances in the Treatment of Hepatorenal Syndrome

Hepatorenal syndrome-vasoconstrictor or vasodilator?

Hepatocardiorenal syndrome in liver cirrhosis: Recognition of a new entity?

Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?

Hepatorenal Syndrome-Acute Kidney Injury in Liver Transplantation

Acute kidney injury and hepatorenal syndrome in cirrhosis

Improving Outcomes in Hepatorenal Syndrome-Acute Kidney Injury With Early Diagnoses and Implementation of Approved Treatment Regimens

Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy

Improving the Management of Hepatorenal Syndrome-Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm

From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury

Pathophysiology of Hepatorenal Syndrome - Acute Kidney Injury

Management of hepatorenal syndrome and treatment-related adverse events

Management of hepatorenal syndrome and associated outcomes: a systematic reviews